Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

FULC

Fulcrum Therapeutics Inc

Mar 06 • 04:00PM ET

8.17

+0.01 0.12 %

Healthcare • Biotechnology • USA • NASD

Peers: VRTX IONS BLUE NBIX SRPT ULTA CRSP EDIT NTLA SGMO

| Held by: VTI IWM VXF IBB IWN VTWO SCHA DFAS ITOT VHT

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.18	Insider Own	14.85%	Shs Outstand	66.58M	Perf Week	-2.51%
Market Cap	544.12M	Forward P/E	-	EPS next Y	-1.56	Insider Trans	-29.93%	Shs Float	56.71M	Perf Month	-17.47%
Enterprise Value	198.25M	PEG	-	EPS next Q	-0.29	Inst Own	88.00%	Short Float	6.20%	Perf Quarter	-9.82%
Income	-74.88M	P/S	-	EPS this Y	-7.85%	Inst Trans	27.53%	Short Ratio	2.37	Perf Half Y	18.75%
Sales	0.00M	P/B	1.56	EPS next Y	-22.91%	ROA	-23.89%	Short Interest	3.52M	Perf YTD	-27.76%
Book/sh	5.24	P/C	1.54	EPS next 5Y	2.55%	ROE	-25.30%	52W High	15.74 -48.09%	Perf Year	153.73%
Cash/sh	5.29	P/FCF	-	EPS past 3/5Y	21.49% 15.80%	ROIC	-21.21%	52W Low	2.32 252.92%	Perf 3Y	36.85%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	8.08% 8.41%	Perf 5Y	-31.97%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-498.13%	Oper. Margin	-	ATR (14)	0.79	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	27.40	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	36.40	Recom	1.50
Dividend Gr. 3/5Y	- -	Current Ratio	27.40	EPS Q/Q	-0.65%	SMA20	-15.30%	Beta	3.30	Target Price	19.00
Payout	-	Debt/Eq	0.02	Sales Q/Q	-	SMA50	-20.33%	Rel Volume	0.52	Prev Close	8.16
Employees	55	LT Debt/Eq	0.01	Earnings	Feb 24 BMO	SMA200	-6.57%	Avg Volume	1.49M	Price	8.17
IPO	Jul 18, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	-3.64% -	Trades		Volume	767,292	Change	0.12%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-12-26	Initiated	JP Morgan	Overweight	$20
Nov-24-25	Initiated	Truist	Buy
Jul-29-25	Upgrade	H.C. Wainwright	Neutral → Buy	$4 → $12
May-23-25	Upgrade	Leerink Partners	Market Perform → Outperform	$12
May-15-25	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$10
Sep-13-24	Downgrade	H.C. Wainwright	Buy → Neutral	$17 → $4
Sep-12-24	Downgrade	Stifel	Buy → Hold
Sep-12-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$15 → $4
Sep-12-24	Downgrade	Leerink Partners	Outperform → Market Perform	$4
Sep-12-24	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Sep-12-24	Downgrade	BofA Securities	Neutral → Underperform	$10 → $2
Sep-09-24	Upgrade	BofA Securities	Underperform → Neutral	$5 → $10
May-20-24	Initiated	Cantor Fitzgerald	Overweight	$23
Mar-13-24	Initiated	RBC Capital Mkts	Outperform	$14
Sep-25-23	Initiated	Goldman	Neutral	$5
Aug-23-23	Upgrade	H.C. Wainwright	Neutral → Buy	$5 → $14
Aug-22-23	Upgrade	Stifel	Hold → Buy	$4 → $11
May-04-23	Downgrade	Goldman	Buy → Neutral	$9 → $3
Mar-10-23	Downgrade	H.C. Wainwright	Buy → Neutral	$20 → $6
Mar-10-23	Downgrade	Credit Suisse	Outperform → Neutral	$11 → $8

Show Previous Ratings

Mar-06-26 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-03-26 08:30AM	Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference (GlobeNewswire)
Feb-25-26 10:27AM	Fulcrum Therapeutics move lower overdone, says Stifel (TipRanks)
Feb-24-26 08:05PM	Fulcrum Therapeutics, Inc. Q4 2025 Earnings Call Summary (Moby) -21.21%
11:47AM	Fulcrum Therapeutics Q4 Earnings Call Highlights (MarketBeat)
09:48AM	Loading…
09:48AM	What's Going On With Fulcrum Therapeutics Stock Tuesday? (Benzinga)
07:01AM	Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025 (GlobeNewswire)
07:00AM	Fulcrum Therapeutics Announces Positive 12-Week Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease (GlobeNewswire)
Feb-17-26 08:00AM	Fulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease (GlobeNewswire)
Feb-12-26 09:55AM	Wall Street Analysts See a 75.71% Upside in Fulcrum Therapeutics (FULC): Can the Stock Really Move This High? (Zacks)
Feb-06-26 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.03%
Jan-09-26 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-07-26 08:00AM	Fulcrum Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-30-25 09:55AM	Wall Street Analysts Think Fulcrum Therapeutics (FULC) Could Surge 58.47%: Read This Before Placing a Bet (Zacks) -5.42%
Dec-21-25 07:31AM	Bullish Analyst Sentiment on Fulcrum Therapeutics (FULC) Following Positive Updates from Phase 1b PIONEER Study (Insider Monkey)
07:48AM	Loading…
Dec-10-25 07:48AM	Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) -5.48%
Dec-08-25 04:01PM	Fulcrum Therapeutics Announces Proposed $150.0 Million Public Offering of Common Stock (GlobeNewswire) +45.96% +12.39%
Dec-06-25 05:30PM	Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting (GlobeNewswire)
Dec-05-25 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +45.96%
Dec-02-25 08:30AM	Fulcrum Therapeutics to Host Investor Event to Review New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease on December 7, 2025 (GlobeNewswire) -9.32%
Nov-20-25 12:33PM	AGIO Stock Hits 52-Week Low on Mixed Sickle Cell Disease Study Results (Zacks)
Nov-19-25 04:20PM	Why Agios Plummeted, Losing Half Its Value, While Fulcrum Surged (Investor's Business Daily) +18.29%
Nov-07-25 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-06-25 09:45AM	Caterpillar upgraded, Elf Beauty downgraded: Wall Street's top analyst calls (The Fly)
Nov-03-25 04:45PM	Fulcrum Therapeutics to Present New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting (GlobeNewswire) -7.21%
Oct-29-25 07:00AM	Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2025 (GlobeNewswire) -6.40%
Oct-22-25 08:54AM	Fulcrum Therapeutics to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Wednesday, October 29, 2025, at 8:00 a.m. ET (GlobeNewswire) -6.80%
Oct-14-25 07:00AM	Fulcrum Therapeutics to Present Preclinical Data for EED Inhibitor FTX-6274 at European Society for Medical Oncology (ESMO) Congress 2025 (GlobeNewswire)
Oct-10-25 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.55%
Sep-12-25 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Loading…
Aug-26-25 08:00AM	Fulcrum Therapeutics to Present at Upcoming Investor Meetings (GlobeNewswire)
Aug-08-25 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-29-25 06:48AM	Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025 (GlobeNewswire)
06:45AM	Fulcrum Therapeutics Announces Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease (GlobeNewswire)
Jul-28-25 04:01PM	Fulcrum Therapeutics to Present Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease (GlobeNewswire)
Jul-11-25 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-06-25 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-30-25 01:17AM	Fulcrum Therapeutics, Inc. (FULC): A Bull Case Theory (Insider Monkey)
May-29-25 04:10PM	Fulcrum Therapeutics to Present at Upcoming Medical Meetings (GlobeNewswire)
08:30AM	Fulcrum Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference (GlobeNewswire)
May-09-25 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.77%
May-08-25 04:05PM	Fulcrum Therapeutics to Participate in Upcoming May Conferences (GlobeNewswire) +6.71%
May-02-25 03:03AM	Fulcrum Therapeutics Inc (FULC) Q1 2025 Earnings Call Highlights: Strategic Cost Reductions and ... (GuruFocus.com) +28.31%
01:27AM	Q1 2025 Fulcrum Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
May-01-25 01:55PM	Fulcrum Therapeutics, Inc. (FULC) Q1 2025 Earnings Call Transcript (Seeking Alpha) +13.77%
07:00AM	Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2025 (GlobeNewswire)
Apr-24-25 08:00AM	Fulcrum Therapeutics to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 8:00 a.m. ET (GlobeNewswire)
Apr-11-25 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +8.55%
Mar-26-25 10:17AM	The Risk/Reward Of Avidity Biosciences And Its 2 Promising Programs (SeekingAlpha)
Mar-04-25 04:05PM	Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference (GlobeNewswire)
Feb-26-25 02:04AM	Fulcrum Therapeutics Inc (FULC) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com) -10.27%
01:28AM	Q4 2024 Fulcrum Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-25-25 07:00AM	Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2024 (GlobeNewswire)
01:52AM	Earnings To Watch: Fulcrum Therapeutics Inc (FULC) Reports Q4 2024 Result (GuruFocus.com)
Feb-18-25 04:05PM	Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast on Tuesday, February 25, 2025, at 8:00 a.m. ET (GlobeNewswire)
Feb-07-25 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-06-25 04:05PM	Fulcrum Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Nov-28-24 12:00PM	Fulcrum Therapeutics (FULC) Upgraded to Buy: Here's Why (Zacks)
Nov-26-24 04:05PM	Fulcrum Therapeutics to Participate in Upcoming December Conferences (GlobeNewswire) +11.27%
Nov-14-24 02:07AM	Fulcrum Therapeutics Inc (FULC) Q3 2024 Earnings Call Highlights: Strategic Advancements Amidst ... (GuruFocus.com) -6.74%
Nov-13-24 07:00AM	Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2024 (GlobeNewswire)
Nov-12-24 04:05PM	Fulcrum Therapeutics to Participate in the Stifel Healthcare Conference (GlobeNewswire)
Nov-06-24 08:00AM	Fulcrum Therapeutics to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, November 13, 2024 at 8:00 a.m. ET (GlobeNewswire)
Oct-18-24 08:00AM	Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up (Investor's Business Daily)
Oct-11-24 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.42%
Oct-09-24 03:30PM	Fulcrum Therapeutics Inc (FULC) Q2 2024 Earnings Call Highlights: Strong Financial Performance ... (GuruFocus.com)
Oct-07-24 03:02PM	FMR LLC's Strategic Reduction in Fulcrum Therapeutics Inc Shares (GuruFocus.com) -6.54%
Oct-04-24 09:35AM	Down -57.53% in 4 Weeks, Here's Why Fulcrum Therapeutics (FULC) Looks Ripe for a Turnaround (Zacks)
Sep-17-24 01:30AM	RA Capital Management's Strategic Acquisition of Fulcrum Therapeutics Shares (GuruFocus.com) +9.75%
Sep-16-24 09:35AM	Fulcrum Therapeutics (FULC) Loses -65.58% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Sep-13-24 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.56%
Sep-12-24 11:32AM	Fulcrum Therapeutics Suspends Rare Muscular Disease Candidate After Disappointing Data From Pivotal Trial (Benzinga) -61.13%
08:10AM	Fulcrum shares collapse as Sanofi-partnered muscular dystrophy drug fails key test (BioPharma Dive)
06:55AM	Fulcrum Therapeutics Announces Topline Results from Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) (GlobeNewswire)
Sep-09-24 02:28PM	Fulcrum Therapeutics Upgraded: BofA Debates Pivotal Study Success For Losmapimod In Rare Genetic Muscle Disease (Benzinga)
Aug-27-24 04:05PM	Fulcrum Therapeutics to Participate in Upcoming September Conferences (GlobeNewswire) -9.09%
Aug-23-24 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.22%
Aug-21-24 09:55AM	Wall Street Analysts Believe Fulcrum Therapeutics (FULC) Could Rally 71.02%: Here's is How to Trade (Zacks)
Aug-19-24 07:00AM	Fulcrum Therapeutics Strengthens Leadership Team with the Appointments of Isabel Kalofonos as Chief Commercial Officer and Heather Faulds as Chief Regulatory Affairs & Quality Assurance Officer (GlobeNewswire)
Aug-09-24 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-05-24 12:00PM	Fulcrum Therapeutics (FULC) Upgraded to Strong Buy: Here's What You Should Know (Zacks) -11.41%
12:00PM	Fulcrum Therapeutics, Inc. (FULC) Is Up 7.55% in One Week: What You Should Know (Zacks)
09:55AM	Does Fulcrum Therapeutics (FULC) Have the Potential to Rally 68.69% as Wall Street Analysts Expect? (Zacks)
Jul-31-24 07:00AM	Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2024 (GlobeNewswire) +10.34%
Jul-24-24 08:00AM	Fulcrum Therapeutics to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, July 31, 2024, at 8:00 a.m. ET (GlobeNewswire)
Jun-12-24 08:00AM	Fulcrum Therapeutics to Present at the 31st Annual FSHD Society International Research Congress (GlobeNewswire)
Jun-06-24 08:00AM	Fulcrum Therapeutics to Participate in the Goldman Sachs' 45th Annual Global Healthcare Conference (GlobeNewswire)
May-26-24 09:02AM	Goldman Sachs Predicts up to 108% Rally for These 2 Strong Buy Stocks (TipRanks)
May-20-24 07:55AM	Cantor Fitzgerald Initiates Fulcrum Therapeutics at Overweight Rating With $23 Price Target (MT Newswires)
May-15-24 09:55AM	Wall Street Analysts See a 69.15% Upside in Fulcrum Therapeutics (FULC): Can the Stock Really Move This High? (Zacks)
May-14-24 08:55AM	Oppenheimer Cuts Fulcrum Therapeutics Price Target to $14 From $16, Maintains Outperform Rating (MT Newswires) +7.62%
07:49AM	Goldman Sachs Upgrades Fulcrum Therapeutics to Buy From Neutral, Price Target is $15 (MT Newswires)
03:01AM	Fulcrum Therapeutics Inc (FULC) Q1 2024 Earnings Call Transcript Highlights: Strategic ... (GuruFocus.com)
May-13-24 11:53AM	FULC Stock Earnings: Fulcrum Therapeutics Beats EPS for Q1 2024 (InvestorPlace)
11:02AM	Sanofi strikes $1bn deal with Fulcrum for muscular dystrophy drug (Pharmaceutical Technology)
08:45AM	Fulcrum Therapeutics, Sanofi Sign Licensing Deal for Facioscapulohumeral Muscular Dystrophy Treatment (MT Newswires)
08:32AM	Fulcrum Therapeutics Q1 2024 Earnings: Misses Analyst Net Income Projections Amid Strategic ... (GuruFocus.com)
07:47AM	Sanofi gambles $80M on Fulcrums muscular dystrophy drug (BioPharma Dive)
07:23AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
07:00AM	Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024 (GlobeNewswire)

Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company, which develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015, and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Gould Robert J	Director	Feb 02 '26	Sale	10.72	15,000	160,857	454,864	Feb 04 04:10 PM
Gould Robert J	Director	Jan 02 '26	Sale	11.87	15,000	178,089	469,864	Jan 06 04:30 PM
Oltmans Curtis Gale	Chief Legal Officer	Dec 15 '25	Sale	12.92	3,452	44,600	10,252	Dec 17 04:10 PM
CURTIS G OLTMANS	Officer	Dec 15 '25	Proposed Sale	13.00	3,452	44,876		Dec 15 04:32 PM
RA CAPITAL MANAGEMENT, L.P.	10% Owner	Dec 08 '25	Sale	13.98	4,175,139	58,377,021	6,053,960	Dec 10 04:42 PM
RA Capital Healthcare Fund LP	10% Owner	Dec 08 '25	Proposed Sale	12.99	4,175,139	54,235,056		Dec 08 05:40 PM
Gould Robert J	Director	Nov 19 '25	Sale	11.03	15,000	165,495	484,864	Nov 21 04:15 PM
ROBERT J GOULD	Director	Nov 19 '25	Proposed Sale	9.73	45,000	437,850		Nov 19 04:20 PM
Tourangeau Greg	Principal Accounting Officer	May 08 '25	Sale	5.06	498	2,520	14,062	May 09 04:15 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

FULC

Fulcrum Therapeutics Inc

Upgrade your FINVIZ experience